CHRIS AMOS to Antineoplastic Agents
This is a "connection" page, showing publications CHRIS AMOS has written about Antineoplastic Agents.
Connection Strength
0.117
-
Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023 08; 98(8):1214-1222.
Score: 0.101
-
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016 May; 209(5):195-8.
Score: 0.015